Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding Ltd.    ROG   CH0012032048

ROCHE HOLDING LTD. (ROG)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Roche : Trastuzumab Treatment for HER-2-Expressing Tumors Need Not Delay Breast Reconstruction Following Mastectomy

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/04/2017 | 02:04pm CET

CHICAGO, Oct. 3 -- The American College of Surgeons issued the following news release:

Treatment with trastuzumab (Herceptin/Genentech) of breast cancers that express the HER-2 protein does not increase the risk for complications at the surgical site for women who undergo immediate breast reconstruction after mastectomy. The first study to assess the effect of trastuzumab on surgical wound complications indicates that breast reconstruction need not be delayed because of the type or length of this form of adjuvant therapy. (Adjuvant therapy is treatment that is given in addition to the primary or main form of treatment to maximize effectiveness.) Study results appear as an "article in press" on the Journal of the American College of Surgeons website in advance of print.

However, combination therapy involving trastuzumab and pertuzumab (Perjeta/Genentech) may carry an increased risk for wound complications after immediate breast reconstruction. Therefore, authors of the study advise surgeons and patients to consider delaying breast reconstruction in otherwise high-risk patients until completion of the full course of treatment if pertuzumab is added to the neoadjuvant regimen. "If a patient is otherwise fairly healthy and the surgery is straightforward, immediate breast reconstruction may be done even if she is receiving both therapies. If a patient has other risk factors and faces a potentially difficult operation, I would recommend waiting until the completion of pertuzumab therapy," said Scott Hollenbeck, MD, FACS, principal author of the study and a plastic and reconstructive surgeon at Duke University Medical Center, Durham, N.C.

Twenty percent of invasive breast cancers have tumors that express the growth factor protein HER-2. These tumors tend to grow and spread more rapidly than other forms of breast cancer.1

Trastuzumab is a monoclonal antibody that targets the HER-2 protein. When given in conjunction with conventional chemotherapy, trastuzumab has increased overall survival, 10-year survival, and disease-free survival of patients with HER-2+ breast cancer.1

Pertuzumab is also used in the treatment of HER-2+ breast tumors. The monoclonal antibody was approved in 2012 for combination therapy with trastuzumab to treat the small number of patients with HER-2-expressing tumors that have metastasized, were larger than 2 cm, involved lymph nodes, or were inflammatory or locally advanced. The addition of pertuzumab to trastuzumab and chemotherapy has prolonged survival for patients with metastatic disease.2

The concern for surgeons who perform breast reconstruction after mastectomy is whether suppression of the HER-2 protein affects the integrity of the skin and therefore increases a patient's susceptibility for wound infection or breakdown at the surgical site. "During surgical reconstruction of the breast after mastectomy, the skin is saved and an implant or flap is inserted underneath. If the skin doesn't heal or dies, the reconstruction could fail and require another operation. Trastuzumab and pertuzumab block the action of HER-2, which is associated with the epidermis or outer layer of the skin. Up to now, there haven't been any studies of the outcomes after breast reconstruction in patients who received these agents. We conducted this study to determine whether trastuzumab alone or in combination with pertuzumab negatively affected breast reconstruction outcomes," Dr. Hollenbeck said.

Investigators at Duke University identified all patients who had breast reconstruction after mastectomy between 2006 and 2016. Of the total of 481 women, the researchers compared outcomes in two matched groups of 107 patients. One group received trastuzumab with or without pertuzumab; the other did not. Patients were matched by age, obesity, diabetes, tobacco use, and type of oncologic treatment regimen.

Overall, the rate of wound breakdown that required a return to surgery for treatment was higher in patients who received both trastuzumab and pertuzumab. The use of trastuzumab alone was not associated with any complication at the surgical site, including bleeding, swelling, coagulation or clotting, disruption of the layers of skin around the surgical incision, or cellular death in the mastectomy skin flap.

"At the present time, there are no clear clinical guidelines on the optimal timing for breast reconstruction. While preliminary, this study may be helpful for guiding the decision by patients and surgeons," Dr. Hollenbeck said.

Findings from the study need to be validated in larger, prospective studies. Until then, the study results "may help surgeons feel more comfortable performing immediate breast reconstruction on patients who receive trastuzumab and delaying the surgery for those on combination targeted HER-2 treatment," he concluded.

Other study authors are Ronnie L. Shammas, BS; Eugenia H. Cho, BSc; Adam D. Glener, BS; Luke P. Poveromo, BS; Lily R. Mundy, MD; Rachel A. Greenup, MD, MPH; and Kimberly L. Blackwell, MD.

"FACS" designates that a surgeon is a Fellow of the American College of Surgeons.

Citation: Association between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity-Matched Analysis. Journal of American College of Surgeons: http://www.journalacs.org/article/S1072-7515(17)31928-2/abstract

Foot notes:-

1. Perez EA et al. Trastuzumab plus adjuvant chemotherapy for human EGF receptor 2 positive breast cancer: Planned joint analysis of overall survival from HSABP B-31 and NCCTG N 9831. J Clin Oncol, 32 (33), Nov 2014; 3744-3752.

2. Swain SMS et al. Pertuzumab, trastuzumab, and docetaxel in HER 2-positive metastasis breast cancer. N Engl J Med 2015 Feb 19; 372 (8): 724-34.

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ROCHE HOLDING LTD.
11:41a IONIS PHARMACEUTICALS : scores huge breakthrough in Huntingtons, Roche licenses ..
11:20a ROCHE : Genentech researchers uncover epigenetic regulator of pancreatic cancer ..
11:12a ABBVIE : Roche boast stellar PhIII leukemia data for a breakthrough combo with b..
07:15a ROCHE : Researchers identify epigenetic orchestrator of pancreatic cancer cells
12/12 ROCHE : Join a Webinar with the Director of Corporate Credit at Roche Diagnostic..
12/12 ROCHE : Genentech's Hemlibra Continued to Substantially Reduce Bleeds in People ..
12/12 ROCHE : Phase II data showed Roche's investigational polatuzumab vedotin plus be..
12/12 ROCHE : Phase II Data Showed Genentech's Investigational Polatuzumab Vedotin Plu..
12/12 ROCHE : announces phase III data showing Venclexta/Venclyxto plus MabThera/Ritux..
12/12 GENENTECH : Announces Phase III Data Showing Venclexta Plus Rituxan Reduced the ..
More news
News from SeekingAlpha
12/12 3 THINGS IN BIOTECH YOU SHOULD LEARN : December 12, 2017
12/12 Combination of AbbVie's venetoclax and Rituxan successful in late-stage leuke..
12/12 YOUR DAILY PHARMA SCOOP : Gilead Remains Long-Term Story, Argenx Rallies, Bluebi..
12/11 Roche Delivers Some Clinical Wins, But Skepticism Remains Largely Intact
12/11 Tecentriq/Avastin combo beats Pfizer's Sutent in late-stage kidney cancer stu..
Financials ( CHF)
Sales 2017 53 500 M
EBIT 2017 18 164 M
Net income 2017 10 965 M
Debt 2017 10 098 M
Yield 2017 3,56%
P/E ratio 2017 18,18
P/E ratio 2018 16,67
EV / Sales 2017 4,09x
EV / Sales 2018 3,86x
Capitalization 209 B
Chart ROCHE HOLDING LTD.
Duration : Period :
Roche Holding Ltd. Technical Analysis Chart | ROG | CH0012032048 | 4-Traders
Technical analysis trends ROCHE HOLDING LTD.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 30
Average target price 274  CHF
Spread / Average Target 13%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
John Irving Bell Non-Executive Director
Andreas Oeri Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING LTD.3.40%209 423
JOHNSON & JOHNSON21.53%379 175
NOVARTIS12.01%218 773
PFIZER10.04%215 837
MERCK AND COMPANY-6.96%153 659
AMGEN19.97%128 363